Skip to main content
. Author manuscript; available in PMC: 2017 Sep 14.
Published in final edited form as: J Med Chem. 2016 Jan 22;59(11):5172–5208. doi: 10.1021/acs.jmedchem.5b01697

Table 5.

Resistance profile of inhibitor 29

Virusa EC50 values, µM
(fold change)
DRV 29
HIV-1ERS104pre (WT) 0.004 0.029
HIV-1B (MDR) 0.019 (5) 0.075 (3)
HIV-1C (MDR) 0.011 (3) 0.030 (1)
HIV-1G (MDR) 0.011 (3) 0.039 (1)
HIV-1TM (MDR) 0.028 (7) 0.074 (3)
a

Amino acid substitutions in the protease-encoding region compared to type B: L63P in HIV-1ERS104pre; L10I, K14R, L33I, M36I, M46I, F53I, K55R, I62V, L63P, A71V, G73S, V82A, L90M, and I93L in HIV-1B; L10I, I15V, K20R, L24I, M36I, M46L, I54V, I62V, L63P, K70Q,V82A, and L89M in HIV-1C; L10I, V11I, T12E, I15V, L19I, R41K, M46L, L63P, A71T, V82A, and L90M in HIV-1G; L10I, K14R, R41K, M46L, I54V, L63P, A71V, V82A, L90M, I93L in HIV-1TM.